NASDAQ:FIXX - Homology Medicines Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $27.91 +1.42 (+5.36 %) (As of 03/19/2019 02:12 AM ET)Previous Close$26.49Today's Range$26.4199 - $28.2852-Week Range$15.07 - $31.80Volume139,470 shsAverage Volume135,851 shsMarket Capitalization$1.05 billionP/E Ratio-13.96Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalitiesgene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts. Receive FIXX News and Ratings via Email Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FIXX Previous Symbol CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone781-301-7277Debt Debt-to-Equity RatioN/A Current Ratio13.24 Quick Ratio13.24Price-To-Earnings Trailing P/E Ratio-13.96 Forward P/E Ratio-14.03 P/E GrowthN/A Sales & Book Value Annual Sales$3.68 million Price / Sales284.70 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($2.00) Net Income$-29,990,000.00 Net Margins-1,553.07% Return on Equity-44.01% Return on Assets-25.70%Miscellaneous EmployeesN/A Outstanding Shares37,539,000Market Cap$1.05 billion Next Earnings Date5/13/2019 (Estimated) OptionableNot Optionable Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions What is Homology Medicines' stock symbol? Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX." How were Homology Medicines' earnings last quarter? Homology Medicines Inc (NASDAQ:FIXX) issued its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.07. The company earned $0.98 million during the quarter. Homology Medicines had a negative return on equity of 44.01% and a negative net margin of 1,553.07%. View Homology Medicines' Earnings History. When is Homology Medicines' next earnings date? Homology Medicines is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for Homology Medicines. What price target have analysts set for FIXX? 7 analysts have issued 1 year price objectives for Homology Medicines' shares. Their predictions range from $18.50 to $37.00. On average, they anticipate Homology Medicines' stock price to reach $30.5833 in the next year. This suggests a possible upside of 9.6% from the stock's current price. View Analyst Price Targets for Homology Medicines. What is the consensus analysts' recommendation for Homology Medicines? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines. Has Homology Medicines been receiving favorable news coverage? Media coverage about FIXX stock has been trending negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Homology Medicines earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. Who are some of Homology Medicines' key competitors? Some companies that are related to Homology Medicines include Amedisys (AMED), ACADIA Pharmaceuticals (ACAD), Hikma Pharmaceuticals (HIK), Ablynx (ABLYF), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Immunomedics (IMMU), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), LHC Group (LHCG), Omnicell (OMCL), China Biologic Products (CBPO), ABCAM PLC/ADR (ABCZY) and Intercept Pharmaceuticals (ICPT). What other stocks do shareholders of Homology Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include NVIDIA (NVDA), Global Blood Therapeutics (GBT), Micron Technology (MU), Alibaba Group (BABA), BioTelemetry (BEAT), Intel (INTC), AT&T (T), Neurocrine Biosciences (NBIX), Portola Pharmaceuticals (PTLA) and Corbus Pharmaceuticals (CRBP). Who are Homology Medicines' key executives? Homology Medicines' management team includes the folowing people: Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63)Mr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory BoardDr. Siyamak Rasty Ph.D., Chief Operating Officer (Age 55) When did Homology Medicines IPO? (FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager. Who are Homology Medicines' major shareholders? Homology Medicines' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (5.63%), RTW Investments LP (4.36%), BlackRock Inc. (3.89%), VV Manager LLC (2.06%), Lord Abbett & CO. LLC (0.74%) and Northern Trust Corp (0.48%). Company insiders that own Homology Medicines stock include James E Flynn, Kush Parmar, Ventures Iv LP 5Am and Vida Ventures, Llc. View Institutional Ownership Trends for Homology Medicines. Which institutional investors are selling Homology Medicines stock? FIXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Lord Abbett & CO. LLC, Sphera Funds Management LTD. and Victory Capital Management Inc.. Company insiders that have sold Homology Medicines company stock in the last year include Kush Parmar and Ventures Iv LP 5Am. View Insider Buying and Selling for Homology Medicines. Which institutional investors are buying Homology Medicines stock? FIXX stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, BlackRock Inc., VV Manager LLC, Polar Capital LLP, Northern Trust Corp, Geode Capital Management LLC, Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines. How do I buy shares of Homology Medicines? Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Homology Medicines' stock price today? One share of FIXX stock can currently be purchased for approximately $27.91. How big of a company is Homology Medicines? Homology Medicines has a market capitalization of $1.05 billion and generates $3.68 million in revenue each year. The company earns $-29,990,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. What is Homology Medicines' official website? The official website for Homology Medicines is http://www.homologymedicines.com. How can I contact Homology Medicines? Homology Medicines' mailing address is One Patriots Park, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277. MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 47 (Vote Outperform)Underperform Votes: 40 (Vote Underperform)Total Votes: 87MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What is the Stochastic Momentum Index (SMI)?